Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor presented as a solution for injection for intravenous and subcutaneous use. It treats neutropenia associated with chemotherapy and other conditions in patients requiring increased neutrophil production.

GNH USA supplies Neupogen as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen, a granulocyte colony‑stimulating factor, is used to stimulate neutrophil production in several hematologic conditions.

- Chemotherapy‑induced neutropenia: reduces the duration of neutropenia and lowers infection risk in patients receiving cytotoxic chemotherapy. - Bone marrow transplantation: accelerates neutrophil recovery after autologous or allogeneic transplantation. - Severe chronic neutropenia: increases neutrophil counts in patients with congenital or idiopathic chronic neutropenia. - Aplastic anemia: supports neutrophil production during treatment of this bone‑marrow failure syndrome. - Peripheral blood stem cell mobilization: enhances mobilization of CD34+ stem cells for collection prior to transplantation.

Neupogen may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bone pain: mild to moderate discomfort often occurring in the limbs or back. - Injection site reactions: redness, swelling, or tenderness at the administration site. - Fever: transient elevation of body temperature. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain requiring immediate medical attention. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Anaphylaxis: rapid onset of allergic reaction with hives, swelling, or airway compromise. - Leukocytosis: excessively high white‑blood‑cell count. - Capillary leak syndrome: fluid accumulation leading to low blood pressure and edema.

Before initiating Neupogen therapy, clinicians should consider several safety measures.

- Dose adjustment in renal impairment: monitor neutrophil counts and adjust as needed. - Use with caution in patients with splenomegaly: monitor for abdominal pain or signs of splenic injury. - Hypersensitivity: avoid in individuals with known allergy to filgrastim or any excipients. - Concomitant myeloid growth factors: do not co‑administer unless specifically directed. - Pregnancy Category C: weigh potential benefits against risks and discuss with obstetric specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neupogen can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other myeloid growth factors (e.g., sargramostim): may cause excessive leukocytosis. - Improper timing with high‑dose chemotherapy: can increase risk of severe myelosuppression.

Moderate Interactions (Monitor Closely): - Corticosteroids: may blunt neutrophil response, requiring closer count monitoring. - Antimicrobial agents (e.g., quinolones): can mask infection signs, necessitating vigilance. - Immunosuppressants (e.g., cyclosporine): may alter neutrophil recovery dynamics, warranting regular assessment.